Meetings - The ASCO Post

The results of ECHELON-1 were presented by David J. Straus, MD, of Memorial Sloan Kettering Cancer Center, New York, at the 2022 National Comprehensive Cancer Network (NCCN) Annual Congress: Hematolog...

Leukemia

By Alice Goodman / November 10, 2022 / 2022 NCCN Annual Congress: Hematologic Malignancies

With Newer Therapies, AML Diagnosis and Prognosis Evolve

For many years, treatment options for acute myeloid leukemia (AML) were limited mainly to the 7 + 3 regimen. However, more recently, a mini-explosion of AML therapies aimed at newly identified genetic...

Lymphoma

Immunotherapy

By Alice Goodman / November 10, 2022 / 2022 NCCN Annual Congress: Hematologic Malignancies

High-Dose Chemotherapy and Stem Cell Transplant vs CAR T-Cell Therapy for Resistant DLBCL

Which is the preferred second-line treatment option for patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL): high-dose chemotherapy and autologous stem cell transplantation (ASC...

2022 NCCN Annual Congress: Hematologic Malignancies

ECHELON-1 Shows Benefit for First-Line Brentuximab Vedotin Plus AVD in Advanced Hodgkin Lymphoma

With Newer Therapies, AML Diagnosis and Prognosis Evolve

High-Dose Chemotherapy and Stem Cell Transplant vs CAR T-Cell Therapy for Resistant DLBCL

Outcomes of Immune Checkpoint Inhibitor Treatment for Cancer in Black vs White Patients in the U.S. VHA System

Pooled Analysis of Long-Term Outcomes With Nivolumab With or Without Ipilimumab in Advanced Melanoma

Neuro-Oncology Guidelines Reveal How AI Could Improve Brain Cancer Diagnosis Monitoring and Treatment

Firefighters May Be Exposed to Chemicals Associated With Breast Cancer

What Is the Impact of a Colon or Colorectal Cancer Diagnosis on Younger Adults?